Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?
Marta ForteAntonio D'AmatiLuisa LimongelliMassimo CorsaliniGianfranco FaviaGiuseppe IngravalloGiuseppe BarileSaverio CapodiferroPublished in: Healthcare (Basel, Switzerland) (2024)
The patient suspended Denosumab for more than six months before teeth extraction for MRONJ prevention; hence, failure to discontinue Osimertinib led us to consider it a possible etiological factor. From a literature analysis, only one case has already been published reporting a possible Osimertinib-related occurrence of MRONJ in lung cancer patients. Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- healthcare
- bone mineral density
- ejection fraction
- newly diagnosed
- systematic review
- chronic kidney disease
- mental health
- risk assessment
- adverse drug
- emergency department
- randomized controlled trial
- clinical trial
- body composition
- open label
- case report
- postmenopausal women
- peritoneal dialysis
- data analysis
- trauma patients